Prevalence and risk factors for the development of dyskinesia among Filipino patients with Parkinson's disease: A 7 year retrospective study.
- Author:
Shiong Shu Leah L
;
Jamora Roland Dominic
- Publication Type:Journal Article
- MeSH: Human; Female; Antiparkinson Agents; Disease Susceptibility; Dopamine Agonists; Dyskinesias; Kaplan-meier Estimate; Levodopa; Parkinson Disease; Prevalence
- From: Philippine Journal of Neurology 2012;16(1):49-
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND: The development of dyskinesia in patients with Parkinson's Disease (PD) has been associated with several risk factors, including the use of Levodopa.
OBJECTIVES: To determine the prevalence of dyskinesia among Filipino patients with Parkinson's Disease given Levodopa versus Dopamine Agonist. To determine the time to development of dyskinesia among Filipino PD patients given Levodopa versus Dopamine Agonists, and to determine the risk factors for the development of dyskinesia among patients on Levodopa.
METHODS: In this retrospective case-control study, the occurrence of dyskinesia was evaluated in 367 PD patiems given Levodopa or Dopamine Agonists.
RESULTS: The prevalence of dyskinesia was significand higher in patients on Levodopa compared to those on DopamineAgonist (36.11% vs 0.86%, p 0.005). Kaplan Meier survival curve showed that at 9 years of treatment, a greater proportion of patients in the dopamine agonist group remained free of dyskinesia compared to the levodopa group (87 vs 3-5%) Patients in the Dopamine agonist group had a longer time to dyskinesia at 7 years compared to those in the Levodopa group at 6.25 years (CI 2 - 20 years). Among patients on Levodopa younger at onset of PD (53.29 vs. 62.37, p < 0.05), female sex (60.44 vs. 39.56%, p 0.006), and longer duration of treatment (6.25 vs. 3.73, p < 0.05) were significant risk factors for the occurrence of dyskinesia.
CONCLUSION: Among Filipino PD patients, the prevalence of dyskinesia is significantly higher in patients on Levodopa compared to those on Dopamine Agonists (36.11% vs 0.8%). At 9 years of treatment, a greater proportion of patients in the DA group remained free of dyskinesia compared to the L-dopa group (87% vs 37.5%). Patients on DAs also had a longer time to the onset dyskinesia at 7 years of treatment compared to those in the L-dopa group at 6.25 years (range at 2 - 20 years of treatment). Among patients on L-dopa, the significant risk factors that predispose patients to the development of dyskinesia are: younger age, female sex, and longer duration of treatment.